Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

Tracey M. Farragher; Mark Lunt; Darren Plant; Diane K. Bunn; Anne Barton; Deborah P. M. Symmons

doi:10.1002/acr.20207

Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

Tracey M. Farragher, Mark Lunt, Darren Plant, Diane K. Bunn, Anne Barton, Deborah P. M. Symmons

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Abstract

Objective To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) testing in predicting both functional outcome and response to treatment in early inflammatory polyarthritis (IP) patients. Methods A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5 years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or steroids over 5 years, early (

Original language	English
Pages (from-to)	664-675
Number of pages	12
Journal	Arthritis Care & Research
Volume	62
Issue number	5
DOIs	https://doi.org/10.1002/acr.20207
Publication status	Published - May 2010

Access to Document

10.1002/acr.20207Licence: Unspecified

Cite this

@article{05b6a92076e14300a8e53c4ee2174acb,

title = "Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies",

abstract = "Objective To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) testing in predicting both functional outcome and response to treatment in early inflammatory polyarthritis (IP) patients. Methods A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5 years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or steroids over 5 years, early (",

author = "Farragher, {Tracey M.} and Mark Lunt and Darren Plant and Bunn, {Diane K.} and Anne Barton and Symmons, {Deborah P. M.}",

year = "2010",

month = may,

doi = "10.1002/acr.20207",

language = "English",

volume = "62",

pages = "664--675",

journal = "Arthritis Care & Research",

issn = "2151-4658",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

AU - Farragher, Tracey M.

AU - Lunt, Mark

AU - Plant, Darren

AU - Bunn, Diane K.

AU - Barton, Anne

AU - Symmons, Deborah P. M.

PY - 2010/5

Y1 - 2010/5

N2 - Objective To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) testing in predicting both functional outcome and response to treatment in early inflammatory polyarthritis (IP) patients. Methods A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5 years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or steroids over 5 years, early (

AB - Objective To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF) testing in predicting both functional outcome and response to treatment in early inflammatory polyarthritis (IP) patients. Methods A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5 years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or steroids over 5 years, early (

U2 - 10.1002/acr.20207

DO - 10.1002/acr.20207

M3 - Article

SN - 2151-4658

VL - 62

SP - 664

EP - 675

JO - Arthritis Care & Research

JF - Arthritis Care & Research

IS - 5

ER -